According to the official website of the U.S. House of Representatives, the House Committee on Oversight and Reform will hold a hearing this week titled "Oversight of the Food and Drug Administration." Robert Califf, the Commissioner of the Food and Drug Administration, will testify and answer questions about the agency's regulation of tobacco and nicotine products.
The purpose of this hearing is to review the ongoing investigations by the oversight committee into the FDA's handling of various issues, including the infant formula crisis, food safety, drug shortages, facility inspections, cannabis regulation, tobacco and nicotine product regulation, as well as over-the-counter decongestants.
The oversight committee emphasized several crises that have occurred within the FDA's regulatory scope, pointing out that these events have had a negative impact on the lives and health of American citizens and families. Chairman of the oversight committee, James Comer, stated that they will be requesting the FDA Commissioner to explain the actions taken in response to the current crises, inspection measures to prevent nationwide crises in the future, and steps to ensure the primary protection of American consumers.
The hearing will be held on Thursday, April 11, 2024 at 1:00 PM Eastern Time, with witnesses including FDA Commissioner Dr. Robert Califf. The hearing will be open to the public and media, and will be live-streamed on https://oversight.house.gov/.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
